Brett Sandercock - ResMed CFO and Principal Accounting Officer
RMD Stock | USD 183.78 0.44 0.24% |
CFO
Mr. Brett A. Sandercock is Chief Financial Officer of the Company since January 1, 2006. From November 2004 until December 2005, Mr. Sandercock was vice president, treasury and finance at ResMed. Before that, from 1998 to November 2004, Mr. Sandercock was group accountant and then controller at ResMed. From March 1996 to August 1998 he was manager, financial accounting and group reporting at Norton Abrasives, a division of the French multinational, Saint Gobain. Mr. Sandercock also held finance and accounting roles from November 1994 to March 1996 at Health Care of Australia, a large private hospital operator in Australia. From 1989 to 1994, Mr. Sandercock worked at PricewaterhouseCoopers in Sydney, specializing in audits of clients predominantly focused on distribution and manufacturing, financial services and technology. Mr. Sandercock holds a B.Ec. from Macquarie University and is a certified chartered accountant. since 2006.
Age | 57 |
Tenure | 18 years |
Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
Phone | 858-836-5000 |
Web | https://www.resmed.com |
Latest Insider Transactions
ResMed Management Efficiency
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M.Similar Executives
Found 14 records | CFO Age | ||
Gregory Matz | The Cooper Companies | 56 | |
William Federici | West Pharmaceutical Services | 57 | |
Jacob Elguicze | Embecta Corp | 51 | |
Scott Lamb | ICU Medical | 55 | |
Stephen Brown | STAAR Surgical | 55 | |
David Murray | Alcon AG | 55 | |
Joel Grade | Baxter International | 53 | |
Robert Hombach | Baxter International | 48 | |
Raul Parra | Merit Medical Systems | 39 | |
Bernard Birkett | Merit Medical Systems | 47 | |
Karleen Oberton | Hologic | 53 | |
MBA BS | Teleflex Incorporated | 62 | |
Robert McMahon | Hologic | 48 | |
Timothy Stonesifer | Alcon AG | 57 |
Management Performance
Return On Equity | 0.22 | ||||
Return On Asset | 0.11 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
AM BE, Chair Founder | ||
John Wareham, Independent Director | ||
Ronald Taylor, Lead Independent Director | ||
Michael Rider, Chief Officer | ||
Gary Pace, Independent Director | ||
Agnes Lee, Senior Director - Investor Relations | ||
Vered Keisar, Chief Officer | ||
Harjit Gill, Independent Director | ||
Kaushik Ghoshal, Chief SaaS | ||
Carol Burt, Independent Director | ||
Rich Sulpizio, Independent Director | ||
Peter Farrell, Non-Executive Chairman of the Board | ||
Jim Hollingshead, President – sleep and respiratory care business | ||
Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit | ||
Jack Wareham, Independent Director | ||
Jan Witte, Independent Director | ||
Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
BE MBA, CEO Director | ||
Anne Reiser, President Europe | ||
Karen Drexler, Independent Director | ||
AM AM, Founder Chairman | ||
Richard McHale, President – Respiratory Care Business | ||
Donald Darkin, President – innovation & operations | ||
Constance Bienfait, Director Relations | ||
Urvashi Tyagi, Chief Technology Officer | ||
Rob Douglas, President COO | ||
Justin Leong, President – Asia and Latin America | ||
Christopher Roberts, Independent Director | ||
Chris Roberts, Independent Director | ||
Robert Douglas, President, Chief Operating Officer | ||
YvonneKatrin Pucknat, Chief Officer | ||
Amy Wakeham, VP Communications | ||
Brett Sandercock, CFO and Principal Accounting Officer | ||
Ron Taylor, Lead Independent Director | ||
Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
Richard Sulpizio, Independent Director | ||
Michael Farrell, Chief Executive Officer, Director | ||
Jim Ellis, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.22 | ||||
Return On Asset | 0.11 | ||||
Profit Margin | 0.20 % | ||||
Operating Margin | 0.29 % | ||||
Current Valuation | 28.27 B | ||||
Shares Outstanding | 147.09 M | ||||
Shares Owned By Insiders | 0.81 % | ||||
Shares Owned By Institutions | 57.23 % | ||||
Number Of Shares Shorted | 7.89 M | ||||
Price To Earning | 73.48 X |
ResMed Investors Sentiment
The influence of ResMed's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ResMed. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ResMed's public news can be used to forecast risks associated with an investment in ResMed. The trend in average sentiment can be used to explain how an investor holding ResMed can time the market purely based on public headlines and social activities around ResMed Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ResMed's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ResMed's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ResMed's news discussions. The higher the estimated score, the more favorable is the investor's outlook on ResMed.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ResMed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ResMed's short interest history, or implied volatility extrapolated from ResMed options trading.
Currently Active Assets on Macroaxis
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.04 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.